HIMS

$HIMS

Hims & Hers Health, Inc.

Telehealth platform for hair loss, sexual health, and wellness.

Healthcare
$20.81
+1.68 (+8.78%)
Day Range$19.05 - $20.88
Prev Close$19.13

HIMS key facts as of November 7, 2026

Latest AI research report
HIMS: Lilly GLP-1 Deal Reframes Growth (as of November 7, 2026)
StockAlpha report sentiment
Neutral (as of November 7, 2026)
Analyst consensus
Hold (2 Strong Buy, 1 Buy, 12 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$31.06 mean (range $24.50 to $40.00) (as of November 12, 2026)
Sector
Healthcare
Analyst Rating
Hold
3 Buy / 12 Hold / 0 Sell
Price Target
$31.06
49.3% upside
Subscribers
2
Tracking this ticker
Latest Report

Analysis from Nov 6, 2026

NEUTRAL

HIMS: Lilly GLP-1 Deal Reframes Growth

HIMS rallied after a landmark distribution deal with Eli Lilly that expands GLP-1 access through its platform. The agreement improves growth visibility but material profitability and balance-sheet questions keep consensus at Hold.

Nov 7, 2026
Read Report

Previous Reports

HIMS: Growth vs Legal Overhang

Oct 31, 2026

HIMS: Subscription Growth vs Legal Headwinds (HIMS)

Oct 24, 2026

HIMS: Novo Deal, Reset, and Valuation (HIMS)

Mar 30, 2026

HIMS: Novo Deal Resets Growth Outlook

Mar 22, 2026

HIMS FAQ

What is StockAlpha's latest view on HIMS?

StockAlpha's latest AI research report on Hims & Hers Health, Inc. (HIMS), "HIMS: Lilly GLP-1 Deal Reframes Growth", was published on November 7, 2026 and rates the overall sentiment as neutral. HIMS rallied after a landmark distribution deal with Eli Lilly that expands GLP-1 access through its platform. The agreement improves growth visibility but material profitability and balance-sheet questions keep consensus at Hold.

When was the HIMS research last updated?

The most recent HIMS report was published on November 7, 2026.

What do analysts expect for HIMS?

As of November 1, 2026, the analyst consensus on HIMS is Hold (2 Strong Buy, 1 Buy, 12 Hold, 0 Sell, 0 Strong Sell). As of November 12, 2026, the analyst price target is $31.06 mean (range $24.50 to $40.00).

Is this HIMS research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring

Explore More Content